Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 118

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 118
---
 of ultraviolet, or UV, light. It can be introduced
into narrow bone crevices or large spaces, open or closed.

GelrinC is specifically designed
for the repair of articular cartilage defects in the knee caused by acute trauma or repetitive use. It is delivered directly to fill
the injury site using a delivery device, Stelar, which seals the lesion during the procedure, and through which the GelrinC liquid is
delivered, and from which the curing UV light is projected. Once the liquid GelrinC has filled the defect, it is cured in place into
an elastomeric implant by photo-curing under UV light for 90 seconds. The implant then starts eroding in conjunction with the advancing
cartilage tissue from the outside edges of the lesion inward. Following a period of approximately six to nine months, the implant is
completely eroded, resorbed and the injury’s surface is covered by newly formed hyaline-like cartilage produced by the patient’s
own body. The primary mode of action of GelrinC is presenting a smooth, impenetrable, neutral surface to the reproduced cartilage cells.
The enabling surface erosion completes this mechanism with a receding implant in a planned synchrony with the newly formed cartilage
tissue.

<div align='center'>72</div>

Mode of Action of GelrinC:

| 1. Stelar delivery device                                                                                                                
 membrane covers cartilage lesion. Using a syringe GelrinC is introduced into the lesion.                                                 |     | 2. Upon filing of the lesion,                                                                   
 UV beam cures GelrinC into a soft rubbery implant.                                              |
| 3. As GelrinC implant recedes                                                                                                            
 and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue filling up the void created by the retreating implant. |     | 4. At the end of 6-9 months                                                                     
 with functioning knee, GelrinC implant is resorbed and new cartilage covers the treated lesion. |

<div align='center'>73</div>

As demonstrated in the Pilot
Study, the advantages of GelrinC include:

| ● | An off-the-shelf product 
 for cartilage repair;    |

| ● | A new class of a-cellular 
 product solution;         |

| ● | Polyethylene glycol, or                                                                                                             
 PEG, implant preventing cellular migration as a primary mode of action and further aided by